Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(cetuximab). Showing records 1 – 30 of 53 total matches.

[1] [2]

Search Limiters

Last 2 Years | English Only

▼ Search Limiters


Universitat Autònoma de Barcelona

1. Pueyo Castells, Gemma. Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia.

Degree: Departament de Biologia Cel·lular i de Fisiologia, 2010, Universitat Autònoma de Barcelona

 Hyperactivity of Epidermal Growth Factor Receptor (EGFR) in cancer patients is associated with poor prognosis. EGFR is overexpressed in a wide range of tumors, including… (more)

Subjects/Keywords: Càncer; Cetuximab; EGFR; Ciències Experimentals; 573

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pueyo Castells, G. (2010). Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia. (Thesis). Universitat Autònoma de Barcelona. Retrieved from http://hdl.handle.net/10803/3837

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Pueyo Castells, Gemma. “Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia.” 2010. Thesis, Universitat Autònoma de Barcelona. Accessed March 04, 2021. http://hdl.handle.net/10803/3837.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Pueyo Castells, Gemma. “Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia.” 2010. Web. 04 Mar 2021.

Vancouver:

Pueyo Castells G. Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia. [Internet] [Thesis]. Universitat Autònoma de Barcelona; 2010. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10803/3837.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Pueyo Castells G. Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia. [Thesis]. Universitat Autònoma de Barcelona; 2010. Available from: http://hdl.handle.net/10803/3837

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Oxford

2. Kareemaghay, Sedigeh. Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma.

Degree: PhD, 2014, University of Oxford

 Epithermal Growth Factor Receptor (EGFR) is overexpressed in up to 90% of head and neck squamous cell carcinoma (HNSCC). Cetuximab is the first and the… (more)

Subjects/Keywords: 616.99; Medical sciences; Oncology; cetuximab; resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kareemaghay, S. (2014). Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma. (Doctoral Dissertation). University of Oxford. Retrieved from http://ora.ox.ac.uk/objects/uuid:dd59b38e-ac07-4a6b-b458-74397b76d883 ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639980

Chicago Manual of Style (16th Edition):

Kareemaghay, Sedigeh. “Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma.” 2014. Doctoral Dissertation, University of Oxford. Accessed March 04, 2021. http://ora.ox.ac.uk/objects/uuid:dd59b38e-ac07-4a6b-b458-74397b76d883 ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639980.

MLA Handbook (7th Edition):

Kareemaghay, Sedigeh. “Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma.” 2014. Web. 04 Mar 2021.

Vancouver:

Kareemaghay S. Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma. [Internet] [Doctoral dissertation]. University of Oxford; 2014. [cited 2021 Mar 04]. Available from: http://ora.ox.ac.uk/objects/uuid:dd59b38e-ac07-4a6b-b458-74397b76d883 ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639980.

Council of Science Editors:

Kareemaghay S. Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma. [Doctoral Dissertation]. University of Oxford; 2014. Available from: http://ora.ox.ac.uk/objects/uuid:dd59b38e-ac07-4a6b-b458-74397b76d883 ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639980

3. Marzi, Laetitia. Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer.

Degree: Docteur es, Biologie Santé, 2014, Université Montpellier I

 Le cetuximab est une thérapie ciblée dirigée contre le récepteur du facteur de croissance épidermique (EGFR) utilisée dans le cancer colorectal (CCR) en combinaison avec… (more)

Subjects/Keywords: Cancer colorectal; Cetuximab; P38mapk; P53; Échec thérapeutique; Inhibiteurs EGFR; Colorectal cancer; Cetuximab; P38mapk; P53; Therapies; EGFR inhibitors; 616

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Marzi, L. (2014). Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer. (Doctoral Dissertation). Université Montpellier I. Retrieved from http://www.theses.fr/2014MON13525

Chicago Manual of Style (16th Edition):

Marzi, Laetitia. “Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer.” 2014. Doctoral Dissertation, Université Montpellier I. Accessed March 04, 2021. http://www.theses.fr/2014MON13525.

MLA Handbook (7th Edition):

Marzi, Laetitia. “Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer.” 2014. Web. 04 Mar 2021.

Vancouver:

Marzi L. Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer. [Internet] [Doctoral dissertation]. Université Montpellier I; 2014. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2014MON13525.

Council of Science Editors:

Marzi L. Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal : Implication of p38 and p53 in cetuximab mechanism of action in colorectal cancer. [Doctoral Dissertation]. Université Montpellier I; 2014. Available from: http://www.theses.fr/2014MON13525

4. 진, 성호. Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma.

Degree: 2014, Ajou University

Intraperitoneal (i.p.) radioimmunotherapy (RIT) may be a promising treatment strategy for intraperitoneally-confined malignant diseases including malignant ascites (MA) in gastric cancer. We conducted a comparative… (more)

Subjects/Keywords: Stomach neoplasm; epidermal growth factor receptor; ascites; intraperitoneal; radioimmunotherapy; radioimmunoconjugates; cetuximab; 64Cu-DOTA-cetuximab; positron emission tomography; biodistribution

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

진, . (2014). Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma. (Thesis). Ajou University. Retrieved from http://repository.ajou.ac.kr/handle/201003/10919 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000016000

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

진, 성호. “Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma.” 2014. Thesis, Ajou University. Accessed March 04, 2021. http://repository.ajou.ac.kr/handle/201003/10919 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000016000.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

진, 성호. “Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma.” 2014. Web. 04 Mar 2021.

Vancouver:

진 . Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma. [Internet] [Thesis]. Ajou University; 2014. [cited 2021 Mar 04]. Available from: http://repository.ajou.ac.kr/handle/201003/10919 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000016000.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

진 . Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma. [Thesis]. Ajou University; 2014. Available from: http://repository.ajou.ac.kr/handle/201003/10919 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000016000

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Toronto

5. Qiu, Yi. Synthesis and Characterization of EGFR-Targeted Immunoporphysomes.

Degree: 2018, University of Toronto

Many nanosized drug delivery systems rely on the phenomena of enhanced permeability and retention (EPR) effect for their accumulation at the tumor site. However, recent… (more)

Subjects/Keywords: cetuximab; EGFR; multimodal imaging agent; nanoparticle; porphyrins; porphysomes; 0572

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Qiu, Y. (2018). Synthesis and Characterization of EGFR-Targeted Immunoporphysomes. (Masters Thesis). University of Toronto. Retrieved from http://hdl.handle.net/1807/89548

Chicago Manual of Style (16th Edition):

Qiu, Yi. “Synthesis and Characterization of EGFR-Targeted Immunoporphysomes.” 2018. Masters Thesis, University of Toronto. Accessed March 04, 2021. http://hdl.handle.net/1807/89548.

MLA Handbook (7th Edition):

Qiu, Yi. “Synthesis and Characterization of EGFR-Targeted Immunoporphysomes.” 2018. Web. 04 Mar 2021.

Vancouver:

Qiu Y. Synthesis and Characterization of EGFR-Targeted Immunoporphysomes. [Internet] [Masters thesis]. University of Toronto; 2018. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/1807/89548.

Council of Science Editors:

Qiu Y. Synthesis and Characterization of EGFR-Targeted Immunoporphysomes. [Masters Thesis]. University of Toronto; 2018. Available from: http://hdl.handle.net/1807/89548


Virginia Commonwealth University

6. SAXENA, GUNJAN. SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES.

Degree: MS, Biomedical Engineering, 2012, Virginia Commonwealth University

 A tumor targeted dendrimer based drug delivery system was designed and synthesized to carry chemotherapy drug doxorubicin. Polyamidoamine (PAMAM) dendrimer G4.5 was chosen as the… (more)

Subjects/Keywords: PAMAM; DOXORUBICIN; CETUXIMAB; DENDRIMER; Biomedical Engineering and Bioengineering; Engineering

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

SAXENA, G. (2012). SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES. (Thesis). Virginia Commonwealth University. Retrieved from https://doi.org/10.25772/FN9Q-EM16 ; https://scholarscompass.vcu.edu/etd/2788

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

SAXENA, GUNJAN. “SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES.” 2012. Thesis, Virginia Commonwealth University. Accessed March 04, 2021. https://doi.org/10.25772/FN9Q-EM16 ; https://scholarscompass.vcu.edu/etd/2788.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

SAXENA, GUNJAN. “SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES.” 2012. Web. 04 Mar 2021.

Vancouver:

SAXENA G. SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES. [Internet] [Thesis]. Virginia Commonwealth University; 2012. [cited 2021 Mar 04]. Available from: https://doi.org/10.25772/FN9Q-EM16 ; https://scholarscompass.vcu.edu/etd/2788.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

SAXENA G. SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMAB-PAMAM DENDRIMER BIOCONJUGATES. [Thesis]. Virginia Commonwealth University; 2012. Available from: https://doi.org/10.25772/FN9Q-EM16 ; https://scholarscompass.vcu.edu/etd/2788

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

7. Okada, Yasuyuki. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response.

Degree: 博士(医学), 2017, Tokushima University / 徳島大学

Subjects/Keywords: Colorectal cancer; EGFR; cetuximab; internalization

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Okada, Y. (2017). EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response. (Thesis). Tokushima University / 徳島大学. Retrieved from http://repo.lib.tokushima-u.ac.jp/110960

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Okada, Yasuyuki. “EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response.” 2017. Thesis, Tokushima University / 徳島大学. Accessed March 04, 2021. http://repo.lib.tokushima-u.ac.jp/110960.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Okada, Yasuyuki. “EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response.” 2017. Web. 04 Mar 2021.

Vancouver:

Okada Y. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response. [Internet] [Thesis]. Tokushima University / 徳島大学; 2017. [cited 2021 Mar 04]. Available from: http://repo.lib.tokushima-u.ac.jp/110960.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Okada Y. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer : 大腸癌における抗EGFR抗体薬治療後のEGFR Downregulationは抗腫瘍効果を予測する; EGFR Down-regulation Predicts anti-EGFR Response. [Thesis]. Tokushima University / 徳島大学; 2017. Available from: http://repo.lib.tokushima-u.ac.jp/110960

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

8. De Angelis, Maria Laura. Cetuximab effect on human colon cancer stem cells.

Degree: 2014, Università degli Studi di Catania

 Cancer Stem cells (CSCs), recently identified in the majority of solid tumors, are thought to drive tumor growth, giving rise to a cascade of differentiated… (more)

Subjects/Keywords: Area 05 - Scienze biologiche; colorectal cancer, cancer stem cells, Cetuximab

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

De Angelis, M. L. (2014). Cetuximab effect on human colon cancer stem cells. (Thesis). Università degli Studi di Catania. Retrieved from http://hdl.handle.net/10761/1488

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

De Angelis, Maria Laura. “Cetuximab effect on human colon cancer stem cells.” 2014. Thesis, Università degli Studi di Catania. Accessed March 04, 2021. http://hdl.handle.net/10761/1488.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

De Angelis, Maria Laura. “Cetuximab effect on human colon cancer stem cells.” 2014. Web. 04 Mar 2021.

Vancouver:

De Angelis ML. Cetuximab effect on human colon cancer stem cells. [Internet] [Thesis]. Università degli Studi di Catania; 2014. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10761/1488.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

De Angelis ML. Cetuximab effect on human colon cancer stem cells. [Thesis]. Università degli Studi di Catania; 2014. Available from: http://hdl.handle.net/10761/1488

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

9. Rebucci, Magali. Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines.

Degree: Docteur es, Biologie cellulaire, 2010, Université Lille II – Droit et Santé

 Dans le traitement des cancers des voies aérodigestives supérieures (VADS), une approche biologique par des anti-EGFR (Epidermal Growth Factor Receptor) comme le cetuximab (Erbitux®) a… (more)

Subjects/Keywords: Cetuximab; Epidermal Growth Factor Receptor

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rebucci, M. (2010). Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines. (Doctoral Dissertation). Université Lille II – Droit et Santé. Retrieved from http://www.theses.fr/2010LIL2S034

Chicago Manual of Style (16th Edition):

Rebucci, Magali. “Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines.” 2010. Doctoral Dissertation, Université Lille II – Droit et Santé. Accessed March 04, 2021. http://www.theses.fr/2010LIL2S034.

MLA Handbook (7th Edition):

Rebucci, Magali. “Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines.” 2010. Web. 04 Mar 2021.

Vancouver:

Rebucci M. Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines. [Internet] [Doctoral dissertation]. Université Lille II – Droit et Santé 2010. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2010LIL2S034.

Council of Science Editors:

Rebucci M. Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures : Mechanisms of resistance to cetuximab and influence of treatment combinations in HNSCC cell lines. [Doctoral Dissertation]. Université Lille II – Droit et Santé 2010. Available from: http://www.theses.fr/2010LIL2S034

10. Coliat, Pierre. Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity.

Degree: Docteur es, Aspects moléculaires et cellulaires de la biologie, 2015, Université de Strasbourg

Les traitements des cancers des VADS reposent sur la chirurgie, la radiothérapie, et la chimiothérapie. Malgré ces traitements, la survie globale des patients à 5… (more)

Subjects/Keywords: Radiothérapie; Cancers des VADS; Cetuximab; EGFR; MTOR; HIF-1; HIF-2; Rapamycine; Radiotherapy; Head and neck cancer; Cetuximab; EGFR; MTOR; HIF-1; HIF-2; Rapamycin; 615.7; 616.99

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Coliat, P. (2015). Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity. (Doctoral Dissertation). Université de Strasbourg. Retrieved from http://www.theses.fr/2015STRAJ067

Chicago Manual of Style (16th Edition):

Coliat, Pierre. “Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity.” 2015. Doctoral Dissertation, Université de Strasbourg. Accessed March 04, 2021. http://www.theses.fr/2015STRAJ067.

MLA Handbook (7th Edition):

Coliat, Pierre. “Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity.” 2015. Web. 04 Mar 2021.

Vancouver:

Coliat P. Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity. [Internet] [Doctoral dissertation]. Université de Strasbourg; 2015. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2015STRAJ067.

Council of Science Editors:

Coliat P. Stratégie de sensibilisation des tumeurs des voies aérodigestives supérieures aux anti-EGFR et résistance induite : induction de HIF-2 et opportunité thérapeutique : Sensitization of head and neck squamous cell carcinoma to anti-EGFR therapy and acquired resistance : HIF-2 induction and therapeutic opportunity. [Doctoral Dissertation]. Université de Strasbourg; 2015. Available from: http://www.theses.fr/2015STRAJ067

11. Azzopardi, Nicolas. Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators.

Degree: Docteur es, Sciences de la Vie et de la Santé, 2011, Université François-Rabelais de Tours

Les anticorps monoclonaux ont révolutionné le traitement de nombreuses pathologies. Cependant, leur pharmacocinétique (PK) et l’influence de leur concentration sur la réponse clinique restent mal… (more)

Subjects/Keywords: Anticorps monoclonaux; Cetuximab; ELISA; Pharmacocinétique; Relation dose-réponse; Survie sans progression; Polymorphisme génétique; Récepteurs Fc; Monoclonal antibodies; Cetuximab; ELISA; Pharmacokinetics; Dose-response relationship; Genetic polymorphism; Fc receptors

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Azzopardi, N. (2011). Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators. (Doctoral Dissertation). Université François-Rabelais de Tours. Retrieved from http://www.theses.fr/2011TOUR3309

Chicago Manual of Style (16th Edition):

Azzopardi, Nicolas. “Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators.” 2011. Doctoral Dissertation, Université François-Rabelais de Tours. Accessed March 04, 2021. http://www.theses.fr/2011TOUR3309.

MLA Handbook (7th Edition):

Azzopardi, Nicolas. “Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators.” 2011. Web. 04 Mar 2021.

Vancouver:

Azzopardi N. Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators. [Internet] [Doctoral dissertation]. Université François-Rabelais de Tours; 2011. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2011TOUR3309.

Council of Science Editors:

Azzopardi N. Apport de la modélisation pharmacocinétique à l'étude de la variabilité de réponse aux anticorps monoclonaux antitumoraux : application au cetuximab : Optimization of the biosafety of the piggyBac transposon for gene transfer using mRNA and insulators. [Doctoral Dissertation]. Université François-Rabelais de Tours; 2011. Available from: http://www.theses.fr/2011TOUR3309

12. Pointreau, Yoann. Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma.

Degree: Docteur es, Sciences de la Vie et de la Santé, 2015, Université François-Rabelais de Tours

Le cetuximab (CTX) est un anticorps monoclonal anti-EGFR indiqué dans les cancers ORL dont les modalités de prescription pourraient être améliorées. Après chimiothérapie d’induction (étude… (more)

Subjects/Keywords: Cetuximab; Cancers ORL; Anaphylaxie; IgE anti-αGal; Pharmacocinétique; Toxicité; Survie; Relation dose-réponse; Cetuximab; Head and neck cancers; Anaphylaxis; Anti-αGal IgE; Pharmacokinetics; Toxicity; Survival; Dose-response relationship

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pointreau, Y. (2015). Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma. (Doctoral Dissertation). Université François-Rabelais de Tours. Retrieved from http://www.theses.fr/2015TOUR3311

Chicago Manual of Style (16th Edition):

Pointreau, Yoann. “Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma.” 2015. Doctoral Dissertation, Université François-Rabelais de Tours. Accessed March 04, 2021. http://www.theses.fr/2015TOUR3311.

MLA Handbook (7th Edition):

Pointreau, Yoann. “Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma.” 2015. Web. 04 Mar 2021.

Vancouver:

Pointreau Y. Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma. [Internet] [Doctoral dissertation]. Université François-Rabelais de Tours; 2015. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2015TOUR3311.

Council of Science Editors:

Pointreau Y. Etude des sources de variabilité de l'efficacité et des effets indésirables du cetuximab chez les patients traités pour un carcinome épidermoïde de la tête et du cou : Study of sources of variability in terms of efficacy and adverse side effects of cetuximab in patients treated for head and neck squamous cell carcinoma. [Doctoral Dissertation]. Université François-Rabelais de Tours; 2015. Available from: http://www.theses.fr/2015TOUR3311

13. 須藤, 利永. microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する.

Degree: 博士(医学), 2015, Gunma University / 群馬大学

学位記番号:医博甲1515

Subjects/Keywords: microRNA-7; colorectal cancer; cetuximab; EGFR

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

須藤, . (2015). microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する. (Thesis). Gunma University / 群馬大学. Retrieved from http://hdl.handle.net/10087/9088

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

須藤, 利永. “microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する.” 2015. Thesis, Gunma University / 群馬大学. Accessed March 04, 2021. http://hdl.handle.net/10087/9088.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

須藤, 利永. “microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する.” 2015. Web. 04 Mar 2021.

Vancouver:

須藤 . microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する. [Internet] [Thesis]. Gunma University / 群馬大学; 2015. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10087/9088.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

須藤 . microRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation : microRNA-7の発現は大腸癌の予後と関連しており、EGFR経路を抑制してセツキ シマブに対する感受性を制御する. [Thesis]. Gunma University / 群馬大学; 2015. Available from: http://hdl.handle.net/10087/9088

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Universidade de Lisboa

14. Simões, André Gonçalo do Espírito Santo. Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer.

Degree: 2011, Universidade de Lisboa

Tese de mestrado em Bioquímica, apresentada à Universidade de Lisboa, através da Faculdade de Ciências, 2011

O cancro e, actualmente, a segunda causa de morte… (more)

Subjects/Keywords: Cancro colorectal; Cetuximab; ERK5; Ferramenta de entrega; miR-143; Teses de mestrado - 2011

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Simões, A. G. d. E. S. (2011). Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer. (Thesis). Universidade de Lisboa. Retrieved from http://www.rcaap.pt/detail.jsp?id=oai:repositorio.ul.pt:10451/8495

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Simões, André Gonçalo do Espírito Santo. “Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer.” 2011. Thesis, Universidade de Lisboa. Accessed March 04, 2021. http://www.rcaap.pt/detail.jsp?id=oai:repositorio.ul.pt:10451/8495.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Simões, André Gonçalo do Espírito Santo. “Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer.” 2011. Web. 04 Mar 2021.

Vancouver:

Simões AGdES. Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer. [Internet] [Thesis]. Universidade de Lisboa; 2011. [cited 2021 Mar 04]. Available from: http://www.rcaap.pt/detail.jsp?id=oai:repositorio.ul.pt:10451/8495.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Simões AGdES. Exploring MEK5/ERK5 signaling and miRNAs as therapeutic strategies in colon cancer. [Thesis]. Universidade de Lisboa; 2011. Available from: http://www.rcaap.pt/detail.jsp?id=oai:repositorio.ul.pt:10451/8495

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

15. M. Ardizzone. A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL.

Degree: 2013, Università degli Studi di Milano

 Mesothelioma is a malignant tumour that arises from mesothelial cells lining the serosal cavities; in most cases it originates in the pleura and in very… (more)

Subjects/Keywords: cetuximab; human malignant pleural mesothelioma; bioluminescence imaging; Settore VET/07 - Farmacologia e Tossicologia Veterinaria

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Ardizzone, M. (2013). A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL. (Thesis). Università degli Studi di Milano. Retrieved from http://hdl.handle.net/2434/216308

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Ardizzone, M.. “A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL.” 2013. Thesis, Università degli Studi di Milano. Accessed March 04, 2021. http://hdl.handle.net/2434/216308.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Ardizzone, M.. “A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL.” 2013. Web. 04 Mar 2021.

Vancouver:

Ardizzone M. A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL. [Internet] [Thesis]. Università degli Studi di Milano; 2013. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/2434/216308.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Ardizzone M. A PRECLINICAL INVESTIGATIVE PLATFORM SETUP, AS A TOOL FOR EVALUATING THE EFFICACY OF CETUXIMAB IN ADDITION TO THE STANDARD HUMAN MALIGNANT MESOTHELIOMA CHEMOTHERAPY PROTOCOL. [Thesis]. Università degli Studi di Milano; 2013. Available from: http://hdl.handle.net/2434/216308

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Texas Medical Center

16. Lee, Heng-Huan. PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE.

Degree: PhD, 2014, Texas Medical Center

  Ribonuclease (RNase) with its catalytic enzyme activity to degrade RNAs has been shown as a diagnostic serum marker for pancreatic cancer and has also… (more)

Subjects/Keywords: EGFR; Ribonuclease; Pancreatic Cancer; Cetuximab; Laboratory and Basic Science Research; Medicine and Health Sciences

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lee, H. (2014). PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/489

Chicago Manual of Style (16th Edition):

Lee, Heng-Huan. “PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE.” 2014. Doctoral Dissertation, Texas Medical Center. Accessed March 04, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/489.

MLA Handbook (7th Edition):

Lee, Heng-Huan. “PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE.” 2014. Web. 04 Mar 2021.

Vancouver:

Lee H. PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE. [Internet] [Doctoral dissertation]. Texas Medical Center; 2014. [cited 2021 Mar 04]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/489.

Council of Science Editors:

Lee H. PANCREATIC RIBONUCLEASE FUNCTIONS AS AN EPIDERMAL GROWTH FACTOR RECEPTOR LIGAND INDEPENDENTLY OF ITS ENZYME ACTIVITY AND CONTRIBUTES TO CETUXIMAB RESISTANCE. [Doctoral Dissertation]. Texas Medical Center; 2014. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/489


Texas Medical Center

17. Savage, David James. UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA.

Degree: PhD, 2018, Texas Medical Center

  Neuroblastoma is the most common malignancy in infants. Overexpression of the epidermal growth factor receptor (EGFR) in neuroblastoma tumors can result in enhanced EGFR… (more)

Subjects/Keywords: Neuroblastoma; UBE4B; Cetuximab; STAT5; EGFR; Cancer Biology; Medicine and Health Sciences; Other Neuroscience and Neurobiology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Savage, D. J. (2018). UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/872

Chicago Manual of Style (16th Edition):

Savage, David James. “UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA.” 2018. Doctoral Dissertation, Texas Medical Center. Accessed March 04, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/872.

MLA Handbook (7th Edition):

Savage, David James. “UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA.” 2018. Web. 04 Mar 2021.

Vancouver:

Savage DJ. UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA. [Internet] [Doctoral dissertation]. Texas Medical Center; 2018. [cited 2021 Mar 04]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/872.

Council of Science Editors:

Savage DJ. UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA. [Doctoral Dissertation]. Texas Medical Center; 2018. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/872


Universitat de Barcelona

18. Mesia Nin, Ricard. Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello.

Degree: Departament de Medicina, 2014, Universitat de Barcelona

 This thesis deals on the clinical development of the monoclonal antibody Cetuximab for the treatment of squamous cell carcinoma of head and neck, at different… (more)

Subjects/Keywords: Càncer de coll; Cáncer de cuello; Neck cancer; Carcinoma; Cetuximab; Ciències de la Salut; 616

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mesia Nin, R. (2014). Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello. (Thesis). Universitat de Barcelona. Retrieved from http://hdl.handle.net/10803/291437

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Mesia Nin, Ricard. “Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello.” 2014. Thesis, Universitat de Barcelona. Accessed March 04, 2021. http://hdl.handle.net/10803/291437.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Mesia Nin, Ricard. “Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello.” 2014. Web. 04 Mar 2021.

Vancouver:

Mesia Nin R. Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello. [Internet] [Thesis]. Universitat de Barcelona; 2014. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10803/291437.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Mesia Nin R. Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello. [Thesis]. Universitat de Barcelona; 2014. Available from: http://hdl.handle.net/10803/291437

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of New Mexico

19. Griego, Anastacia. Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease.

Degree: Biomedical Sciences Graduate Program, 2016, University of New Mexico

  Human papillomaviruses (HPVs) are the most common sexually transmitted infectious agents. They are responsible for >99% of all cervical cancers as well as subsets… (more)

Subjects/Keywords: HPV; EGFR; growth factor receptor; human papillomavirus; cetuximab; cancer; Medicine and Health Sciences

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Griego, A. (2016). Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease. (Doctoral Dissertation). University of New Mexico. Retrieved from https://digitalrepository.unm.edu/biom_etds/155

Chicago Manual of Style (16th Edition):

Griego, Anastacia. “Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease.” 2016. Doctoral Dissertation, University of New Mexico. Accessed March 04, 2021. https://digitalrepository.unm.edu/biom_etds/155.

MLA Handbook (7th Edition):

Griego, Anastacia. “Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease.” 2016. Web. 04 Mar 2021.

Vancouver:

Griego A. Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease. [Internet] [Doctoral dissertation]. University of New Mexico; 2016. [cited 2021 Mar 04]. Available from: https://digitalrepository.unm.edu/biom_etds/155.

Council of Science Editors:

Griego A. Evaluation of the Epidermal Growth Factor Receptor Signaling Pathway as a Therapeutic Target in Human Papillomavirus-Associated Disease. [Doctoral Dissertation]. University of New Mexico; 2016. Available from: https://digitalrepository.unm.edu/biom_etds/155

20. Privitera, Giovanna. Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC).

Degree: 2013, Università degli Studi di Catania

 Il carcinoma del polmone rappresenta attualmente la neoplasia più frequentemente diagnosticata e costituisce la principale causa di morte per tumore solido al mondo. E una… (more)

Subjects/Keywords: Area 06 - Scienze mediche; EGFR, HER-2, trastuzumab, cetuximab, cell proliferation, proliferazione cellulare, MTT, FISH

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Privitera, G. (2013). Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC). (Thesis). Università degli Studi di Catania. Retrieved from http://hdl.handle.net/10761/1436

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Privitera, Giovanna. “Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC).” 2013. Thesis, Università degli Studi di Catania. Accessed March 04, 2021. http://hdl.handle.net/10761/1436.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Privitera, Giovanna. “Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC).” 2013. Web. 04 Mar 2021.

Vancouver:

Privitera G. Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC). [Internet] [Thesis]. Università degli Studi di Catania; 2013. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10761/1436.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Privitera G. Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC). [Thesis]. Università degli Studi di Catania; 2013. Available from: http://hdl.handle.net/10761/1436

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

21. Maugeri, Marco. Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab.

Degree: 2014, Università degli Studi di Catania

 It has been demonstrated that intercellular communication via cell- released vesicles is very important both for normal and tumor cells, and specifically to determine tumor… (more)

Subjects/Keywords: Area 06 - Scienze mediche; Colorectal cancer, microRNAs, proteins, exosomes, cell communication, cetuximab

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Maugeri, M. (2014). Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab. (Thesis). Università degli Studi di Catania. Retrieved from http://hdl.handle.net/10761/1527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Maugeri, Marco. “Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab.” 2014. Thesis, Università degli Studi di Catania. Accessed March 04, 2021. http://hdl.handle.net/10761/1527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Maugeri, Marco. “Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab.” 2014. Web. 04 Mar 2021.

Vancouver:

Maugeri M. Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab. [Internet] [Thesis]. Università degli Studi di Catania; 2014. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10761/1527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Maugeri M. Analysis of the involvement of exosomal miRNAs and proteins in the response of CRC cells to Cetuximab. [Thesis]. Università degli Studi di Catania; 2014. Available from: http://hdl.handle.net/10761/1527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Texas Medical Center

22. Lu, Haiquan. Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation.

Degree: PhD, 2013, Texas Medical Center

  Epidermal growth factor receptor (EGFR) is overexpressed in the majority of head and neck cancers. The anti-EGFR antibody cetuximab has been approved by the… (more)

Subjects/Keywords: EGFR; Cetuximab; Radiation; HIF-1; Warburg effect; Cancer metabolism; Redox homeostasis; ASCT2; Medicine and Health Sciences

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lu, H. (2013). Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/395

Chicago Manual of Style (16th Edition):

Lu, Haiquan. “Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation.” 2013. Doctoral Dissertation, Texas Medical Center. Accessed March 04, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/395.

MLA Handbook (7th Edition):

Lu, Haiquan. “Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation.” 2013. Web. 04 Mar 2021.

Vancouver:

Lu H. Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation. [Internet] [Doctoral dissertation]. Texas Medical Center; 2013. [cited 2021 Mar 04]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/395.

Council of Science Editors:

Lu H. Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation. [Doctoral Dissertation]. Texas Medical Center; 2013. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/395


Université Paris-Sud – Paris XI

23. Chu, Céline. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.

Degree: Docteur es, Pharmacologie experimentale et clinique, 2013, Université Paris-Sud – Paris XI

La P-glycoprotéine (P-gp) est une protéine transmembranaire de la famille des ATP binding cassette transporteurs. Elle est impliquée dans l’efflux du milieu intracellulaire vers le… (more)

Subjects/Keywords: Evérolimus; Lapatinib; Cétuximab; Irinotécan; P-glycoprotéine; Xénogreffe de cancer colorectal; Everolimus; Lapatinib; Cetuximab; Irinotecan; P-glycoprotein; Colorectal carcinoma xenograft

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Chu, C. (2013). Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2013PA114806

Chicago Manual of Style (16th Edition):

Chu, Céline. “Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.” 2013. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed March 04, 2021. http://www.theses.fr/2013PA114806.

MLA Handbook (7th Edition):

Chu, Céline. “Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.” 2013. Web. 04 Mar 2021.

Vancouver:

Chu C. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2013. [cited 2021 Mar 04]. Available from: http://www.theses.fr/2013PA114806.

Council of Science Editors:

Chu C. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2013. Available from: http://www.theses.fr/2013PA114806


Texas Medical Center

24. Liao, Hsin-Wei. Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance.

Degree: PhD, 2015, Texas Medical Center

  Protein modifications of epidermal growth factor receptor (EGFR) intracellular domain are well known regulators of EGFR functions whereas those of its extracellular domain remain… (more)

Subjects/Keywords: PRMT1; EGFR; methylation; cetuximab; colorectal cancer; Medical Cell Biology; Medical Molecular Biology; Medicine and Health Sciences

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Liao, H. (2015). Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/615

Chicago Manual of Style (16th Edition):

Liao, Hsin-Wei. “Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance.” 2015. Doctoral Dissertation, Texas Medical Center. Accessed March 04, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/615.

MLA Handbook (7th Edition):

Liao, Hsin-Wei. “Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance.” 2015. Web. 04 Mar 2021.

Vancouver:

Liao H. Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance. [Internet] [Doctoral dissertation]. Texas Medical Center; 2015. [cited 2021 Mar 04]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/615.

Council of Science Editors:

Liao H. Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance. [Doctoral Dissertation]. Texas Medical Center; 2015. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/615


University of Illinois – Chicago

25. Monberg, Matthew J. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.

Degree: 2016, University of Illinois – Chicago

 Background: Although head and neck cancer (HNC) is the sixth most common cancer type by incidence globally, few studies have focused on real world treatment… (more)

Subjects/Keywords: SEER Medicare; head and neck cancer; HNC; erythropoietin stimulating agents; anemia; supportive care; ESAs; cetuximab; disparities; chemotherapy; radiation

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Monberg, M. J. (2016). Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/20886

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Monberg, Matthew J. “Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.” 2016. Thesis, University of Illinois – Chicago. Accessed March 04, 2021. http://hdl.handle.net/10027/20886.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Monberg, Matthew J. “Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers.” 2016. Web. 04 Mar 2021.

Vancouver:

Monberg MJ. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. [Internet] [Thesis]. University of Illinois – Chicago; 2016. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/10027/20886.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Monberg MJ. Evaluation of the Patterrns and Risks of Erythropoietin Stimulating Agents in Head and Neck Cancers. [Thesis]. University of Illinois – Chicago; 2016. Available from: http://hdl.handle.net/10027/20886

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Adelaide

26. Sree Kumar, Shalini. Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines.

Degree: 2015, University of Adelaide

 Colorectal cancer (CRC) is a leading cause of cancer death worldwide and despite significant improvement the median survival remains relatively poor. The use of targeted… (more)

Subjects/Keywords: biomarkers; resistance; EGFR; anti-EGFR; colorectal cancer; cetuximab; panitumumab; KRAS; G13D; BRAF; HBEGF; AKT3; EGR1; Research by Publication

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Sree Kumar, S. (2015). Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/104679

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Sree Kumar, Shalini. “Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines.” 2015. Thesis, University of Adelaide. Accessed March 04, 2021. http://hdl.handle.net/2440/104679.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Sree Kumar, Shalini. “Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines.” 2015. Web. 04 Mar 2021.

Vancouver:

Sree Kumar S. Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines. [Internet] [Thesis]. University of Adelaide; 2015. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/2440/104679.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Sree Kumar S. Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines. [Thesis]. University of Adelaide; 2015. Available from: http://hdl.handle.net/2440/104679

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

27. Niehr, Franziska. CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab.

Degree: 2016, Freie Universität Berlin

 Zusammenfassung Die wesentlichen ätiologischen Risikofaktoren für Plattenepithelkarzinome des Kopf-Hals-Bereiches (SCCHN) sind der aktive Tabakkonsum bzw. die passive Exposition mit Tabakrauch, sowie Alkoholabusus. Zusätzlich häufen sich… (more)

Subjects/Keywords: HNSCC; cancer; head and neck; cisplatin; cetuximab; temsirolimus; mtor; EGFR; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Niehr, F. (2016). CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-6768

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Niehr, Franziska. “CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab.” 2016. Thesis, Freie Universität Berlin. Accessed March 04, 2021. http://dx.doi.org/10.17169/refubium-6768.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Niehr, Franziska. “CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab.” 2016. Web. 04 Mar 2021.

Vancouver:

Niehr F. CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab. [Internet] [Thesis]. Freie Universität Berlin; 2016. [cited 2021 Mar 04]. Available from: http://dx.doi.org/10.17169/refubium-6768.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Niehr F. CCI-779 (Temsirolimus) weist eine erhöhte Antitumor-Aktivität in Kopf-Hals- Karzinom-Zelllinien mit niedriger EGFR-Expression auf und zeigt Wirksamkeit in Zellen mit erworbener Resistenz gegenüber Cisplatin und Cetuximab. [Thesis]. Freie Universität Berlin; 2016. Available from: http://dx.doi.org/10.17169/refubium-6768

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Iowa

28. Dahl, Rachel A. Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma.

Degree: MS, Pathology, 2018, University of Iowa

  Title: Inhibition of interleukin-6 trans-signaling by sgp130Fc is anti-tumorigenic in head and neck squamous cell carcinoma. Background: Head and neck squamous cell carcinoma (HNSCC)… (more)

Subjects/Keywords: cetuximab; head and neck cancer; head and neck squamous cell carcinoma; interleukin-6 trans-signaling; sgp130Fc; tocilizumab; Pathology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Dahl, R. A. (2018). Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma. (Masters Thesis). University of Iowa. Retrieved from https://ir.uiowa.edu/etd/6091

Chicago Manual of Style (16th Edition):

Dahl, Rachel A. “Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma.” 2018. Masters Thesis, University of Iowa. Accessed March 04, 2021. https://ir.uiowa.edu/etd/6091.

MLA Handbook (7th Edition):

Dahl, Rachel A. “Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma.” 2018. Web. 04 Mar 2021.

Vancouver:

Dahl RA. Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma. [Internet] [Masters thesis]. University of Iowa; 2018. [cited 2021 Mar 04]. Available from: https://ir.uiowa.edu/etd/6091.

Council of Science Editors:

Dahl RA. Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma. [Masters Thesis]. University of Iowa; 2018. Available from: https://ir.uiowa.edu/etd/6091


University of Lund

29. Leon, Otilia. Improved oncological treatment of anal cancer.

Degree: 2019, University of Lund

 AbstractBackground: Squamous cell cancer of the anus (SCCA) is a rare malignancy, but the incidence is increasing. It isassociated with humman papilloma virus infection. The… (more)

Subjects/Keywords: Medical and Health Sciences; Anal cancer; chemotherapy; Radiotherapy; Prognosis and survival; phase I/II trial; Cetuximab; metastatic

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Leon, O. (2019). Improved oncological treatment of anal cancer. (Doctoral Dissertation). University of Lund. Retrieved from https://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf

Chicago Manual of Style (16th Edition):

Leon, Otilia. “Improved oncological treatment of anal cancer.” 2019. Doctoral Dissertation, University of Lund. Accessed March 04, 2021. https://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf.

MLA Handbook (7th Edition):

Leon, Otilia. “Improved oncological treatment of anal cancer.” 2019. Web. 04 Mar 2021.

Vancouver:

Leon O. Improved oncological treatment of anal cancer. [Internet] [Doctoral dissertation]. University of Lund; 2019. [cited 2021 Mar 04]. Available from: https://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf.

Council of Science Editors:

Leon O. Improved oncological treatment of anal cancer. [Doctoral Dissertation]. University of Lund; 2019. Available from: https://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf

30. Reveles, Ivan Alexander. Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population.

Degree: MSin Pharmacy, Pharmacy, 2013, University of Texas – Austin

 Introduction: Current treatment recommendations for advanced SCCHN include the use of combined modality therapy (e.g., radiation plus chemotherapy/biologic therapy). The new biologic agent, cetuximab, is… (more)

Subjects/Keywords: Head and neck cancer; Cost; Cetuximab; Economics

…biologic therapy (i.e., cetuximab). 5 Cetuximab is an… …carboplatin, docetaxel, cetuximab, fluorouracil. 5 With the… …cetuximab. 5 Prior to 2006, platinum-­‐based regimens served as… …cetuximab, an epidermal growth factor receptor (EGFR) inhibitor… …carboplatin, docetaxel, cetuximab, and fluorouracil. 5 4… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Reveles, I. A. (2013). Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population. (Masters Thesis). University of Texas – Austin. Retrieved from http://hdl.handle.net/2152/22221

Chicago Manual of Style (16th Edition):

Reveles, Ivan Alexander. “Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population.” 2013. Masters Thesis, University of Texas – Austin. Accessed March 04, 2021. http://hdl.handle.net/2152/22221.

MLA Handbook (7th Edition):

Reveles, Ivan Alexander. “Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population.” 2013. Web. 04 Mar 2021.

Vancouver:

Reveles IA. Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population. [Internet] [Masters thesis]. University of Texas – Austin; 2013. [cited 2021 Mar 04]. Available from: http://hdl.handle.net/2152/22221.

Council of Science Editors:

Reveles IA. Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population. [Masters Thesis]. University of Texas – Austin; 2013. Available from: http://hdl.handle.net/2152/22221

[1] [2]

.